Bariatric surgery has evolved from a surgical measure for treating morbid obesity to an epochal remedy for treating metabolic syndrome as a whole, which is represented by type 2 diabetes mellitus. Numerous clinical trials have advocated bariatric or metabolic surgery over nonsurgical interventions because of markedly superior metabolic outcomes in morbidly obese patients who satisfy traditional criteria for bariatric surgery (body mass index [BMI] >35 kg/m 2 ) and in less obese or simply overweight patients. Nevertheless, not all diabetes patients achieve the most desirable outcomes; i.e., diabetes remission after metabolic surgery. Thus, candidates for metabolic surgery should be carefully selected based on comprehensive preoperative assessments of the risk-benefit ratio. Predictors for diabetes remission after metabolic surgery may be classified into two groups based on mechanism of action. The first is indices for preserved pancreatic beta-cell function, including younger age, shorter duration of diabetes, and higher C-peptide level. The second is the potential for an insulin resistance reduction, including higher baseline BMI and visceral fat area. Several prediction models for diabetes remission have been suggested by merging these two to guide the joint decision-making process between clinicians and patients. Three such models, DiaRem, ABCD, and individualized metabolic surgery scores, provide an intuitive scoring system and have been validated in an independent external cohort and can be utilized in routine clinical practice. These prediction models need further validation in various ethnicities to ensure universal applicability.
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is an increasing pandemic affecting >400 million people worldwide. 1 Unfortunately, approximately one third of these diabetes patients live in the Asia-Pacific area. The risk of developing T2DM is greater for obese Asians than for Caucasians with the same body mass index (BMI) because of the higher proportion of body fat and prominent abdominal obesity. 2, 3 T2DM prevalence is also increasing in Korea, from 8.6% in 2001 to 11.0% in 2013 among adults aged ≥ 30 years, according to the Korea National Health and Nutrition Examination Surveys. 4 Despite the rapidly increasing diversity of pharmaceutical options, the control of diabetes over the last decade in Korea has been minimal.
According to the Korean National Survey, which included 1,341 patients with diabetes aged >30 years, only 27% of patients with diabetes met the well-controlled diabetes glycosylated hemoglobin (HbA1c) level <6.5% and only 45.6% achieved an HbA1c <7% in
2012; these values demonstrate the little change made since 2005
and indicate that a breakthrough in the fight against this chronic disease is needed. 5 The efficacy of bariatric surgery on remarkable and sustained weight loss has been well demonstrated in numerous studies [6] [7] [8] [9] , and it is no longer disputable that surgical measures induce distinctly superior outcomes in terms of weight loss compared to any other medical treatments. Along with sustained weight loss, bariatric sur-ties, including T2DM. Since Dr. Pories introduced metabolic surgery in 1995, suggesting surgical treatments as a potential cure for diabetes 10 , several studies have focused on the metabolic effect of bariatric surgery. 8, [11] [12] [13] This trend shifted the paradigm from bariatric surgery, which was aimed at body weight reduction, toward "metabolic surgery, " which primarily intends to treat metabolic diseases, particularly T2DM. Based on extensive evidence, the international diabetes organization, encompassing over 50 medical and surgical societies, released a joint statement in 2016 endorsing metabolic surgery for uncontrolled T2DM patients despite optimal medical management, even for those with class I obesity (BMI, 27.5-32.5 kg/m 2 for Asians). 14 This indirectly reflects that a consensus has been reached that improvement in diabetes mellitus after bariatric surgery is related to mechanisms other than simple weight loss alone, although they are not completely understood yet. 15 Nevertheless, not all diabetes patients achieve the desirable outcome of diabetes remission after surgical treatment. Surgery may also pose nutritional risks requiring long-term monitoring and supplementation in patients. Candidates for metabolic surgery should be selected carefully based on a comprehensive preoperative assessment of the risk-benefit ratio. Although many studies show that baseline BMI does not adequately predict metabolic surgery outcomes 16 , the most current evidence is based on studies using the conventional eligibility criteria of BMI >35 kg/m 2 for bariatric surgery. Selecting patients based on BMI criteria is currently inevitable. However, investigators have argued that more robust diabetesspecific parameters, besides BMI, should be established to identify suitable patients for metabolic surgery and predict postoperative outcomes.
DEFINITION OF DIABETES REMISSION
There has been great heterogeneity in defining diabetes remission in the literature. The rate of diabetes remission following bariatric and metabolic surgery can be largely affected by how remission is defined. Mas-Lorenzo et al. 17 revealed that the remission rate decreased from 92.7% to 43.6% with a more stringent definition of remission in a diabetes patient cohort (n = 55) undergoing a
Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG). 
PREDICTIVE FACTORS OF DIABETES REMISSION FOLLOWING BARIATRIC OR METABOLIC SURGERY
Several studies have investigated outcomes of bariatric surgery in patients with T2DM to identify predictive factors of diabetes remission following surgery (Table 1) . 7, 13, 18, [20] [21] [22] [23] [24] 30 The remission rate ranged from 24% to 84% according to the type of surgery and the baseline characteristics of the patients. As shown in Table 1 , these studies were heterogeneous in terms of sample size, follow-up duration, and definition of remission used.
Interestingly, some factors emerged as common denominators of diabetes remission across these studies despite different surgical types and remission criteria. These included a younger age, higher baseline BMI, shorter duration of diabetes, and better glycemic control before surgery, which may be represented by a lower HbA1c or fasting plasma glucose and no preoperative insulin use (Table 1 ). Some studies suggested that a lower baseline C-peptide level was associated with poor control of diabetes after bariatric surgery. 20 A study of Korean patients demonstrated similar results as those of other studies, including that a baseline C-peptide level >2.6 ng/mL was a prerequisite for diabetes remission and that preoperative BMI, younger age, and a lower HbA1c with no insulin use before the surgery independently predicted diabetes remission 
PREDICTION MODELS OF DIABETES REMISSION

DiaRem score
DiaRem Score was proposed by Still et al. 31 based on a retrospective review of 690 patients with T2DM who underwent RYGB.
They reported a complete or partial remission rate of 63%. They used 259 clinical variables to identify independent predictive factors and to develop a prediction model. They found that patients who required insulin for glycemic control before surgery were 7.25 times less likely to achieve either complete or partial remission after surgery, which was the strongest indicator to predict diabetes remission after bariatric or metabolic surgery. Additionally, age at operation, baseline HbA1c level, and type of antidiabetic medications used before surgery appeared to be predictors irrespective of insulin use. Based on these result, a scoring system ranging from 0 to 22 was established by weighing each variable based on the probability of diabetes remission (Table 2) . Scores were classified into five groups according to the probability of diabetes remission, and a higher score indicated a higher probability of remission. This scoring system was externally validated in an independent population and in several subsequent studies.
32,33
ABCD score ABCD score was devised by Wei-Jei Lee and other representative bariatric surgeons from Asia. 34 They initially reviewed 63 patients who underwent RYGB or single-anastomosis gastric bypass (previously known as mini-gastric bypass) and identified four factors, including age at operation (A), baseline BMI (B), C-peptide level (C), and diabetes duration (D). These factors were used to construct a simple scaling system ranging from 0 to 10. Patients with a higher score are more likely to achieve diabetes remission after surgery.
This original scoring system went through some modifications to enhance the predictive power with very low scores, particularly re- flecting results from the lower BMI population (Table 3) . 35 The modified ABCD scoring system has been tested in 510 patients from different hospitals across Asia and demonstrated very good predictability of diabetes remission from 5.9% to 93.3% along with increase in score. 36 The system was also tested in SG patients and showed good correlation with the diabetes mission rate as well although with lower remission rates compared to gastric bypass patients in the original cohort. 37 This indicates that the type of surgery has a significant influence on glycemic control after metabolic surgery.
Individualized metabolic surgery score
Aminian et al. 38 devised the individualized metabolic surgery 
CONCLUSION
Traditionally, diabetes care has been led by endocrinologists and the relevant medical team, particularly in Korea. As the era of metabolic surgery has begun, surgeons are more likely to be involved in diabetes treatment by providing an active effort to achieve glycemic control with surgical measures.
Optimal outcome following metabolic surgery would be achieving diabetes remission without antidiabetic medication. However, not all diabetes patients achieve diabetes remission after surgery and patients recommended for surgery should be carefully selected to avoid those who may benefit least from surgical procedures.
Bariatric/metabolic surgery is a far better option in improving glucose homeostasis, along with remarkable and sustained weight loss in morbidly obese patients with T2DM. However, the inconsistent results from different studies with the lower BMI population suggests that BMI criterion alone does not adequately predict the probability of diabetes remission in nonmorbidly obese patients undergoing metabolic surgery. Although several randomized controlled studies unanimously advocated metabolic surgery over con- compared ABCD and DiaRem scores, and subsequently with IMS score using data from Taiwanese patients. They suggested that ABCD score is better at predicting T2DM remission after metabolic surgery than both DiaRem and IMS scores. DiaRem and ABCD scores were also tested in the Korean patient who underwent RYGB. 42 Although the overall trend in both scoring systems correlated to actual diabetes remission rates, ABCD score appeared discriminate more in Korean patients. The ABCD score may be superior in predicting diabetes remission or improvement after surgery in the Asian population with a relatively lower BMI. These prediction models with their scoring systems should be further validated in various ethnicities to ensure universal applicability before implementation into clinical practice.
The second Diabetes Surgery Summit made an official announcement that metabolic surgery is recommended as a standard option for T2DM treatment 10 ; therefore, more studies are focusing on therapeutic effects of metabolic surgery in terms of complete cure, i.e., "remission," of this complex chronic disease, which was believed to inevitably worsen over time. Nonetheless, one thing to be cautious about is that remission of diabetes should not be considered as the only goal of metabolic surgery. Most investigators agree that surgical outcome of metabolic surgery with the primary intent to treat T2DM should be considered in the continuum of improving glucose homeostasis and failure to achieve complete diabetes remission should not be considered a failure of surgical treatment. The majority of patients can still benefit from improved glycemic control after metabolic surgery although the degree of benefit may not be enough to satisfy the criteria of remission. Remission of diabetes, based on the current definition, although desirable, should not be regarded as the only goal of metabolic surgery or the only measure of success. Therefore, establishing a universally accepted goal and definition of successful treatment from metabolic surgery is necessary in the larger context of diabetes care
to facilitate judicious patient selection for surgery.
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